i-Base Fit for Purpose report launched at CROI 2019
12 March 2019. Related: Supplements, Conference reports, CROI 26 (Retrovirus) 2019.
Fit for Purpose provides an overview of recent developments in antiretroviral treatment (ART) optimisation for HIV positive adults, in low- and middle-income countries (LMICs).
We produce Fit for Purpose annually for distribution at the International AIDS Society (IAS) conferences, with updates to coincide with other key HIV meetings.
This abbreviated version – looking at optimised ART for adults and including the HIV pipeline – was released at the annual Conference on Retroviruses and Opportunistic Infections (CROI) 2019
Key developments since the July 2018 edition include:
- Interim World Health Organisation guidelines recommending dolutegravir (DTG)-based regimens for all adults and children (for whom approved DTG dosing is available) as preferred first- and second-line ART – published December 2018
- Week 48 results from the NAMSAL study – a key ART optimisation trial of first-line DTG vs efavirenz (EFV) in an African setting – presented October 2018
- Week 48 results from a second-line switch study of people stable on a twice-daily lopinavir/ritonavir (LPV/r)-based regimen who switched to a once-daily 400/100 mg darunavir/ritonavir (DRV/r) one – presented July 2018
- Pharmacokinetic data on tenofovir alafenamide (TAF) pregnancy from IMPAACT P1026s – presented July 2018
We will continue to cover key developments in optimised ART and new drugs and strategies in HTB throughout the year.
The July 2019 update will include ART optimisation for both adults and children and a new section on long acting formulations
Download Fit for Purpose (March 2019)